{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T22:54:35Z","timestamp":1793141675047,"version":"4.5.0"},"reference-count":19,"publisher":"Oxford University Press (OUP)","issue":"2","license":[{"start":{"date-parts":[[2025,12,16]],"date-time":"2025-12-16T00:00:00Z","timestamp":1765843200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"Soligenix, Inc"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,2,4]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>The study was designed to obtain a preliminary assessment of the safety and efficacy of SGX945 (dusquetide) for the treatment of aphthous oral and genital ulcers in Beh\u00e7et\u2019s syndrome.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This was an open-label pilot study of intravenous dusquetide in patients with Beh\u00e7et\u2019s syndrome who had at least two active oral and\/or one active genital ulcer(s) at enrolment. Participants were treated twice weekly for 4\u2009weeks and then followed for an additional 4\u2009weeks. Efficacy assessments included number and pain of oral and genital ulcers, overall disease activity assessed using Beh\u00e7et\u2019s Syndrome Current Activity Form and Beh\u00e7et\u2019s Syndrome Activity Scale and health-related quality of life assessed using Beh\u00e7et\u2019s Syndrome Quality of Life Index.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Eight participants with oral ulcers were enrolled. Seven of eight participants reported a perceived benefit including reduction in number, duration and pain of oral ulcers. Comparison to historical placebo groups demonstrated a reduction in the number of ulcers, time to resolution of ulcers, area under the curve of the ulcer-days, oral pain and baseline quality of life metrics. The treatments were well-tolerated with no treatment-related AEs and no serious or severe adverse events recorded.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>This small pilot study illustrates the potential efficacy and tolerability of SGX945 in patients with Beh\u00e7et\u2019s syndrome who had ulcers despite being on colchicine maintenance therapy. The results justify further development of SGX945 for the treatment of Beh\u00e7et\u2019s syndrome.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Clinical trial registration<\/jats:title>\n                    <jats:p>Clinicaltrials.gov, http:\/\/clinicaltrials.gov, NCT06386744.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/rheumatology\/keaf682","type":"journal-article","created":{"date-parts":[[2025,12,15]],"date-time":"2025-12-15T12:29:52Z","timestamp":1765801792000},"source":"Crossref","is-referenced-by-count":2,"title":["Results from a pilot study of dusquetide for the treatment of aphthous ulcers associated with Beh\u00e7et's syndrome"],"prefix":"10.1093","volume":"65","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9879-3031","authenticated-orcid":false,"given":"Oreola","family":"Donini","sequence":"first","affiliation":[{"name":"Soligenix, Inc. , Princeton, NJ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0895-8865","authenticated-orcid":false,"given":"Bercemhan","family":"Sulu","sequence":"additional","affiliation":[{"name":"Cerrahpa\u015fa Medical Faculty, Division of Rheumatology, Department of Internal Medicine, Istanbul University \u2013 Cerrahpa\u015fa , Istanbul, T\u00fcrkiye"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-4763-9957","authenticated-orcid":false,"given":"Christopher","family":"Pullion","sequence":"additional","affiliation":[{"name":"Soligenix, Inc. , Princeton, NJ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam","family":"Rumage","sequence":"additional","affiliation":[{"name":"Soligenix, Inc. , Princeton, NJ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-6257-6775","authenticated-orcid":false,"given":"Richard","family":"Straube","sequence":"additional","affiliation":[{"name":"Soligenix, Inc. , Princeton, NJ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher","family":"Schaber","sequence":"additional","affiliation":[{"name":"Soligenix, Inc. , Princeton, NJ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1952-1135","authenticated-orcid":false,"given":"G\u00fclen","family":"Hatemi","sequence":"additional","affiliation":[{"name":"Cerrahpa\u015fa Medical Faculty, Division of Rheumatology, Department of Internal Medicine, Istanbul University \u2013 Cerrahpa\u015fa , Istanbul, T\u00fcrkiye"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,12,16]]},"reference":[{"key":"2026022606024916200_keaf682-B1","doi-asserted-by":"crossref","first-page":"80","DOI":"10.55563\/clinexprheumatol\/ra8ize","article-title":"Apremilast for oral ulcers associated with active Beh\u00e7et\u2019s syndrome over 68 weeks: long-term results from a phase 3 randomised clinical trial","volume":"39(Suppl 132)","author":"Hatemi","year":"2021","journal-title":"Clin Exp Rheumatol"},{"key":"2026022606024916200_keaf682-B2","first-page":"3","article-title":"One year in review 2020: beh\u00e7et\u2019s syndrome","volume":"38(Suppl 127)","author":"Hatemi","year":"2020","journal-title":"Clin Exp Rheumatol"},{"key":"2026022606024916200_keaf682-B3","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1038\/nrrheum.2017.208","article-title":"Beh\u00e7et syndrome: a contemporary view","volume":"14","author":"Yazici","year":"2018","journal-title":"Nat Rev Rheumatol"},{"key":"2026022606024916200_keaf682-B4","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1186\/s13075-021-02615-7","article-title":"Epidemiology and treatment of Behcet\u2019s disease in the USA: insights from the Rheumatology Informatics System for Effectiveness (RISE) Registry with a comparison with other published cohorts from endemic regions","volume":"23","author":"Hammam","year":"2021","journal-title":"Arthritis Res Ther"},{"key":"2026022606024916200_keaf682-B5","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1016\/S0140-6736(23)02629-6","article-title":"Beh\u00e7et\u2019s syndrome","volume":"403","author":"Emmi","year":"2024","journal-title":"Lancet"},{"key":"2026022606024916200_keaf682-B6","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1080\/03009742.2021.1885735","article-title":"Clinical phenotypes of Behcet\u2019s syndrome in a large cohort of Italian patients: focus on gender differences","volume":"50","author":"Leccese","year":"2021","journal-title":"Scand J Rheumatol"},{"key":"2026022606024916200_keaf682-B7","doi-asserted-by":"crossref","first-page":"1628","DOI":"10.1002\/art.42486","article-title":"Reduction of neutrophil activation by phosphodiesterase 4 blockade in Beh\u00e7et\u2019s Disease","volume":"75","author":"Le Joncour","year":"2023","journal-title":"Arthritis Rheumatol"},{"key":"2026022606024916200_keaf682-B8","doi-asserted-by":"crossref","first-page":"1055753","DOI":"10.3389\/fmed.2023.1055753","article-title":"Innate immune responses in Beh\u00e7et disease and relapsing polychondritis","volume":"10","author":"Shimizu","year":"2023","journal-title":"Front Med (Lausanne)"},{"key":"2026022606024916200_keaf682-B9","doi-asserted-by":"crossref","first-page":"852297","DOI":"10.3389\/fimmu.2022.852297","article-title":"The roles of monocytes and macrophages in Beh\u00e7et\u2019s Disease with focus on M1 and M2 polarization","volume":"13","author":"Hirahara","year":"2022","journal-title":"Front Immunol"},{"key":"2026022606024916200_keaf682-B10","doi-asserted-by":"crossref","first-page":"1109147","DOI":"10.3389\/fimmu.2023.1109147","article-title":"Chemokines and chemokine receptors in Beh\u00e7et\u2019s disease","volume":"14","author":"Li","year":"2023","journal-title":"Front Immunol"},{"key":"2026022606024916200_keaf682-B11","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1136\/annrheumdis-2019-215672","article-title":"2018 Update of the EULAR recommendations for the management of large vessel vasculitis","volume":"79","author":"Hellmich","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"2026022606024916200_keaf682-B12","doi-asserted-by":"crossref","first-page":"1918","DOI":"10.1056\/NEJMoa1816594","article-title":"Trial of apremilast for oral ulcers in Beh\u00e7et\u2019s Syndrome","volume":"381","author":"Hatemi","year":"2019","journal-title":"N Engl J Med"},{"key":"2026022606024916200_keaf682-B13","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.jbiotec.2016.03.032","article-title":"A novel approach for emerging and antibiotic resistant infections: innate Defense Regulators as an agnostic therapy","volume":"226","author":"North","year":"2016","journal-title":"J Biotechnol"},{"key":"2026022606024916200_keaf682-B14","doi-asserted-by":"crossref","first-page":"36007","DOI":"10.1074\/jbc.C109.073627","article-title":"Sequestosome-1\/p62 is the key intracellular target of innate defense regulator peptide","volume":"284","author":"Yu","year":"2009","journal-title":"J Biol Chem"},{"key":"2026022606024916200_keaf682-B15","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.jbiotec.2016.10.010","article-title":"Randomized, placebo-controlled phase 2a clinical and preclinical data demonstrating a significant and consistent reduction in duration of oral mucositis with a novel innate defense regulator","volume":"239","author":"Kudrimoti","year":"2016","journal-title":"J Biotechnol"},{"key":"2026022606024916200_keaf682-B16","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1016\/j.str.2022.05.003","article-title":"Dusquetide modulates innate immune response through binding to p62","volume":"30","author":"Zhang","year":"2022","journal-title":"Structure"},{"key":"2026022606024916200_keaf682-B17","first-page":"931","article-title":"Development of the BD-QoL: a quality of life measure specific to Behcet\u2019s disease","volume":"31","author":"Gilworth","year":"2004","journal-title":"J Rheumatol"},{"key":"2026022606024916200_keaf682-B18","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1093\/rheumatology\/38.8.728","article-title":"Behcet\u2019s disease: evaluation of a new instrument to measure clinical activity","volume":"38","author":"Bhakta","year":"1999","journal-title":"Rheumatology (Oxford)"},{"key":"2026022606024916200_keaf682-B19","first-page":"360","article-title":"Behcet\u2019s Syndrome Activity Score (BSAS): a new disease activity assessment tool, composed of patient-derived measures only, is strongly correlated with the Bechcet\u2019s Disease Current Activity Form (BDCAF)","volume":"67","author":"Forbess","year":"2008","journal-title":"Ann Rheum Dis"}],"container-title":["Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/rheumatology\/advance-article-pdf\/doi\/10.1093\/rheumatology\/keaf682\/65924990\/keaf682.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/rheumatology\/article-pdf\/65\/2\/keaf682\/65924990\/keaf682.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/rheumatology\/article-pdf\/65\/2\/keaf682\/65924990\/keaf682.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T11:02:57Z","timestamp":1772103777000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/rheumatology\/article\/doi\/10.1093\/rheumatology\/keaf682\/8381546"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,16]]},"references-count":19,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,2,4]]}},"URL":"https:\/\/doi.org\/10.1093\/rheumatology\/keaf682","relation":{},"ISSN":["1462-0324","1462-0332"],"issn-type":[{"value":"1462-0324","type":"print"},{"value":"1462-0332","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,2]]},"published":{"date-parts":[[2025,12,16]]},"article-number":"keaf682"}}